Design, Synthesis, and Evaluation of New Mesenchymal–Epithelial Transition Factor (c-Met) Kinase Inhibitors with Dual Chiral Centers
A series of tepotinib derivatives with two chiral centers was designed, synthesized, and evaluated as anticancer agents. The optimal compound <b>(<i>R</i>, <i>S</i>)-12a</b> strongly exhibited antiproliferative activity against MHCC97H cell lines with an IC<sub...
Main Authors: | Han Yao, Yuanyuan Ren, Jun Yan, Jiadai Liu, Jinhui Hu, Ming Yan, Xingshu Li |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/27/17/5359 |
Similar Items
-
Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
by: Sung-Hwa Sohn, et al.
Published: (2022-07-01) -
Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the <i>MET</i> Gene: Doublet Treatment versus Single Agent Treatment
by: Sung-Hwa Sohn, et al.
Published: (2024-02-01) -
Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non‐small cell lung cancer: A case report
by: Satoshi Ikeo, et al.
Published: (2023-04-01) -
First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression
by: Alessandro Inno, et al.
Published: (2023-10-01) -
Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report
by: Liang-Wei Tseng, et al.
Published: (2022-10-01)